Urinary cystatin C as a biomarker for acute kidney injury and its immunohistochemical localization in kidney in the CDDP-treated rats

Experimental and Toxicologic Pathology

Volumn 64, Issue 7-8, 2012, Pages 797-805

  Togashi, Yuko ^a   Sakaguchi, Yuka ^a   Miyamoto, Mari ^a   Miyamoto, Yohei ^a  

^a TORAY INDUSTRIES INC   (Japan)

Author keywords

Acute kidney injury (AKI); Biomarker; Cisplatin (CDDP); Cystatin C; Immunohistochemistry

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CALBINDIN; CISPLATIN; CLUSTERIN; CYSTATIN C; EPIDERMAL GROWTH FACTOR; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE ALPHA; GLUTATHIONE TRANSFERASE MU; KIDNEY INJURY MOLECULE 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOPONTIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; DIAGNOSTIC VALUE; DISEASE COURSE; EARLY DIAGNOSIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY CORTEX; KIDNEY MEDULLA; KIDNEY PARENCHYMA; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE DAMAGE; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; URINE LEVEL;

ACUTE KIDNEY INJURY; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CISPLATIN; CYSTATIN C; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 84867711134     PISSN: 09402993     EISSN: 16181433     Source Type: Journal    
DOI: 10.1016/j.etp.2011.01.018     Document Type: Article

References (48)

1. Abrahamson M., Olafsson I., Palsdottir A., Ulvsbäck M., Lundwall A., Jensson O., et al. Structure and expression of the human cystatin C gene. Biochem J 1990, 268:287-294.
2. Bagshaw SM, Bellomo R. Cystatin C in acute kidney injury. Curr Opin Crit Care 2010.
3. Bailly V., Zhang Z., Meier W., Cate R., Sanicola M., Bonventre J.V. Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. J Biol Chem 2002, 277:39739-39748.
4. Baran D., Tenstad O., Aukland K. Localization of tubular uptake segment of filtered cystatin C and aprotinin in the rat kidney. Acta Physiol (Oxf) 2006, 186:209-221.
5. Betton G.R., Kenne K., Somers R., Marr A. Protein biomarkers of nephrotoxicity; a review and findings with cyclosporin A, a signal transduction kinase inhibitor and N-phenylanthranilic acid. Cancer Biomark 2005, 1:59-67.
6. Coll E., Botey A., Alvarez L., Poch E., Quintó L., Saurina A., et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000, 36:29-34.
7. Dieterle F., Perentes E., Cordier A., Roth D.R., Verdes P., Grenet O., et al. Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol 2010, 28:463-469.
8. European Medicines Agency (EMEA) Final report on the pilot joint EMEA/FDA VXDs experience on qualification of nephrotoxicity biomarkers 2008.
9. Finney H., Newman D.J., Gruber W., Merle P., Price C.P. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA BN II). Clin Chem 1997, 43:1016-1022.
10. Food and Drug Administration (FDA) FDA, European Medicines Agency to consider additional test results when assessing new drug safety 2008.
11. Gatanaga H., Tachikawa N., Kikuchi Y., Teruya K., Genka I., Honda M., et al. Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses 2006, 22:744-748.
12. Gautier J.C., Riefke B., Walter J., Kurth P., Mylecraine L., Guilpin V., et al. Evaluation of novel biomarkers of nephrotoxicity in two strains of rat treated with cisplatin. Toxicol Pathol 2010, 38:943-956.
13. Grubb A. Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol 1992, 38(Suppl. (1)):S20-S27.
14. Håkansson K., Huh C., Grubb A., Karlsson S., Abrahamson M. Mouse and rat cystatin C: Escherichia coli production, characterization and tissue distribution. Comp Biochem Physiol B: Biochem Mol Biol 1996, 114:303-311.
15. Heuer J.G., Sharma G.R., Gerlitz B., Zhang T., Bailey D.L., Ding C., et al. Evaluation of protein C and other biomarkers as predictors of mortality in a rat cecal ligation and puncture model of sepsis. Crit Care Med 2004, 32:1570-1578.
16. Hewitt S.M., Dear J., Star R.A. Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol 2004, 15:1677-1689.
17. Hoffmann D., Fuchs T.C., Henzler T., Matheis K.A., Herget T., Dekant W., et al. Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity. Toxicology 2010, 277:49-58.
18. Hoffmann D., Adler M., Vaidya V.S., Rached E., Mulrane L., Gallagher W.M., et al. Performance of novel kidney biomarkers in preclinical toxicity studies. Toxicol Sci 2010, 116:8-22.
19. Ichimura T., Hung C.C., Yang S.A., Stevens J.L., Bonventre J.V. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol 2004, 286:F552-F563.
20. International Life Sciences Institute Health and Environmental Sciences Institute (ILSI-HESI) Project committee on the development and application of biomarkers of nephrotoxicity 2008.
21. Ishii A., Sakai Y., Nakamura A. Molecular pathological evaluation of clusterin in a rat model of unilateral ureteral obstruction as a possible biomarker of nephrotoxicity. Toxicol Pathol 2007, 35:376-382.
22. Jacobsson B., Lignelid H., Bergerheim U.S. Transthyretin and cystatin C are catabolized in proximal tubular epithelial cells and the proteins are not useful as markers for renal cell carcinomas. Histopathology 1995, 26:559-564.
23. Kuhlmann M.K., Burkhardt G., Köhler H. Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant 1997, 12:2478-2480.
24. Kumar R., Schaefer J., Grande J.P., Roche P.C. Immunolocalization of calcitriol receptor, 24-hydroxylase cytochrome P-450, and calbindin D28k in human kidney. Am J Physiol 1994, 266:F477-F485.
25. Kwon O., Ahn K., Zhang B., Lockwood T., Dhamija R., Anderson D., et al. Simultaneous monitoring of multiple urinary cytokines may predict renal and patient outcome in ischemic AKI. Ren Fail 2010, 32:699-708.
26. 2+ handling. Kidney Int 2006, 69:650-654.
27. Levy E. Cystatin C: a potential target for Alzheimer's treatment. Expert Rev Neurother 2008, 8:687-689.
28. Ma Y., Li Q., Wang J., Xu Z., Song C., Zhuang R., et al. Cystatin C, a novel urinary biomarker for sensitive detection of acute kidney injury during haemorrhagic fever with renal syndrome. Biomarkers 2010, 15:410-417.
29. Madero M., Sarnak M.J. Association of cystatin C with adverse outcomes. Curr Opin Nephrol Hypertens 2009, 18:258-263.
30. Mussap M., Plebani M. Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci 2004, 41:467-550.
31. Nonclercq D., Toubeau G., Lambricht P., Heuson-Stiennon J.A., Laurent G. Redistribution of epidermal growth factor immunoreactivity in renal tissue after nephrotoxin-induced tubular injury. Nephron 1991, 57:210-215.
32. Olafsson I., Grubb A. Hereditary cystatin C amyloid angiopathy. Amyloid 2000, 7:70-79.
33. Ozer J.S., Dieterle F., Troth S., Perentes E., Cordier A., Verdes P., et al. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat Biotechnol 2010, 28:486-494.
34. Palsdottir A., Snorradottir A.O., Thorsteinsson L. Hereditary cystatin C amyloid angiopathy: genetic, clinical, and pathological aspects. Brain Pathol 2006, 6:55-59.
35. Parikh C.R., Lu J.C., Coca S.G., Devarajan P. Tubular proteinuria in acute kidney injury: a critical evaluation of current status and future promise. Ann Clin Biochem 2010, 47:301-312.
36. Rosenberg M.E., Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995, 27:633-645.
37. Safirstein R., Winston J., Goldstein M., Moel D., Dikman S., Guttenplan J. Cisplatin nephrotoxicity. Am J Kidney Dis 1986, 8:356-367.
38. Takashi M., Zhu Y., Miyake K., Kato K. Urinary 28-kD calbindin-D as a new marker for damage to distal renal tubules caused by cisplatin-based chemotherapy. Urol Int 1996, 56:174-179.
39. Tavéra C., Prévot D., Girolami J.P., Leung-Tack J., Collé A. Tissue and biological fluid distribution of cysteine proteinases inhibitor: rat cystatin C. Biol Chem Hoppe Seyler 1990, 371(Suppl.):187-192.
40. Tenstad O., Roald A.B., Grubb A., Aukland K. Renal handling of radiolabelled human cystatin C in the rat. Scand J Clin Lab Invest 1996, 56:409-414.
41. Thielemans N., Lauwerys R., Bernard A. Competition between albumin and low-molecular-weight proteins for renal tubular uptake in experimental nephropathies. Nephron 1994, 66:453-458.
42. Tizon B., Ribe E.M., Mi W., Troy C.M., Levy E. Cystatin C protects neuronal cells from amyloid-beta-induced toxicity. J Alzheimers Dis 2010, 19:885-894.
43. Tonomura Y., Tsuchiya N., Torii M., Uehara T. Evaluation of the usefulness of urinary biomarkers for nephrotoxicity in rats. Toxicology 2010, 273:53-59.
44. Uchino S., Kellum J.A., Bellomo R., Doig G.S., Morimatsu H., Morgera S., et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005, 294:813-818.
45. Vaidya V.S., Ramirez V., Ichimura T., Bobadilla N.A., Bonventre J.V. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 2006, 290:F517-F529.
46. Wasilewska A.M., Zoch-Zwierz W.M. Urinary levels of matrix metalloproteinases and their tissue inhibitors in nephrotic children. Pediatr Nephrol 2008, 23:1795-1802.
47. Wegiel B., Jiborn T., Abrahamson M., Helczynski L., Otterbein L., Persson J.L., et al. Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways. PLoS One 2009, 23(4):e7953.
48. Westhuyzen J., Endre Z.H., Reece G., Reith D.M., Saltissi D., Morgan T.J. Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit. Nephrol Dial Transplant 2003, 18:543-551.